Biomedical Engineering Reference
In-Depth Information
37. Krieger M. (1999) Charting the fate of the “good choles-
terol”: identification and characterization of the high-
density lipoprotein receptor SR-BI. Annu. Rev. Biochem.
68, 523-558.
38. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger
M. (1996) Identification of scavenger receptor SR-BI
as a high density lipoprotein receptor. Science 271(5248),
518-520.
39. Brewer HB, Jr., Fairwell T, LaRue A, Ronan R, Houser A,
Bronzert TJ. (1978) The amino acid sequence of human
APOA-I, an apolipoprotein isolated from high density lip-
oproteins. Biochem. Biophys. Res. Commun. 80(3), 623-630.
40. Zannis VI, Chroni A, Krieger M. (2006) Role of apoA-I,
ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J. Mol.
Med. 84(4), 276-294.
41. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, Kim KY, et al.
(2007) Systemic and specific delivery of small interfering
RNAs to the liver mediated by apolipoprotein A-I. Mol. Ther.
15(6), 1145-1152.
42. Feng M, Cai Q, Shi X, Huang H, Zhou P, Guo X. (2008)
Recombinant high-density lipoprotein complex as a targeting
system of nosiheptide to liver cells. J. Drug Target 16(6),
502-508.
43. Feng M, Cai Q, Huang H, Zhou P. (2008) Liver targeting and
anti-HBV activity of reconstituted HDL-acyclovir palmitate
complex. Eur. J. Pharm. Biopharm. 68(3), 688-693.
44. Counsell RE, Pohland RC. (1982) Lipoproteins as potential
site-specific delivery systems for diagnostic and therapeutic
agents. J. Med. Chem. 25(10), 1115-1120.
45. Balazs Z, Panzenboeck U, Hammer A, Sovic A, Quehen-
berger O, Malle E, et al. (2004) Uptake and transport of high-
density lipoprotein (HDL) and HDL-associated alpha-
tocopherol by an in vitro blood-brain barrier model.
J. Neurochem. 89(4), 939-950.
46. Connelly MA, Williams DL. (2004) Scavenger receptor BI: a
scavenger receptor with a mission to transport high density
lipoprotein lipids. Curr. Opin. Lipidol. 15(3), 287-295.
47. Krieger M. (2001) Scavenger receptor class B type I is a
multiligand HDL receptor that influences diverse physiologic
systems. J. Clin. Invest. 108(6), 793-797.
48. Reboul E, Klein A, Bietrix F, Gleize B, Malezet-Desmoulins
C, Schneider M, et al. (2006) Scavenger receptor class B type
I (SR-BI) is involved in vitamin E transport across the
enterocyte. J. Biol. Chem. 281(8), 4739-4745.
49. Vishnyakova TG, Bocharov AV, Baranova IN, Chen Z,
Remaley AT, Csako G, et al. (2003) Binding and internaliza-
tion of lipopolysaccharide by Cla-1, a human orthologue of
rodent scavenger receptor B1. J. Biol. Chem. 278(25), 22771-
22780.
50. Cao WM, Murao K, Imachi H, Yu X, Abe H, Yamauchi A,
et al. (2004) A mutant high-density lipoprotein receptor
inhibits proliferation of human breast cancer cells. Cancer
Res. 64(4), 1515-1521.
51. Lacko AG, Nair M, Paranjape S, Johnso S, McConathy WJ.
(2002) High density lipoprotein complexes as delivery vehi-
cles for anticancer drugs. Anticancer Res. 22(4), 2045-2049.
52. Lacko AG, Nair M, Paranjape S, Mooberry L, McConathy
WJ. (2006) Trojan horse meets magic bullet to spawn a novel,
highly effective drug delivery model. Chemotherapy 52(4),
171-173.
53. Lou B, Liao XL, Wu MP, Cheng PF, Yin CY, Fei Z. (2005)
High-density lipoprotein as a potential carrier for delivery of a
lipophilic antitumoral drug into hepatoma cells. World
J. Gastroenterol. 11(7), 954-959.
54. McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko
AG. (2008) Evaluation of synthetic/reconstituted high-den-
sity lipoproteins as delivery vehicles for paclitaxel. Anti-
cancer Drugs 19(2), 183-188.
55. Zhang X, Chen B. Recombinant high density lipoprotein
reconstituted with apolipoprotein AI cysteine mutants as
delivery vehicles
for 10-hydroxycamptothecin. Cancer
Lett. 298(1), 26-33.
56. Hamidi M, Foroozesh M, Zarrin A. (2006) Lipoproteins: from
physiological roles to drug delivery potentials. Crit. Rev.
Ther. Drug Carrier Syst. 23(6), 497-523.
57. Fidge NH. (1999) High density lipoprotein receptors, binding
proteins, and ligands. J. Lipid Res. 40(2), 187-201.
58. Jonas A. (1986) Reconstitution of high-density lipoproteins.
Methods Enzymol. 128, 553-582.
59. Wald JH, Krul ES, Jonas A. (1990) Structure of apolipoprotein
A-I in three homogeneous, reconstituted high density lipo-
protein particles. J. Biol. Chem. 265(32), 20037-20043.
60. Fioravanti J, Gonzalez I, Medina-Echeverz J, Larrea E,
Ardaiz N, Gonzalez-Aseguinolaza G, et al. (2011) Anchoring
interferon alpha to apolipoprotein A-I reduces hematological
toxicity while enhancing immunostimulatory properties.
Hepatology 53(6), 1864-1873.
61. Hovorka R, Nanjee MN, Cooke CJ, Miller IP, Olszewski WL,
Miller NE. (2006) Mass kinetics of apolipoprotein A-I in
interstitial fluid after administration of intravenous apo-
lipoprotein A-I/lecithin discs in humans. J. Lipid. Res.
47(5), 975-981.
62. Nanjee MN, Crouse JR, King JM, Hovorka R, Rees SE,
Carson ER, et al. (1996) Effects of intravenous infusion of
lipid-free apo A-I in humans. Arterioscler. Thromb. Vasc.
Biol. 16(9), 1203-1214.
63. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss
DF. (2002) Structural and biological characterization of
pegylated recombinant interferon alpha-2b and its therapeutic
implications. Adv. Drug. Deliv. Rev. 54(4), 547-570.
64. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyana-
than S, Green M, et al. (2001) Improved pharmacokinetic
properties of a polyethylene glycol-modified form of inter-
feron-beta-1a with preserved in vitro bioactivity. J. Pharma-
col. Exp. Ther. 297(3), 1059-1066.
65. Tape C, Kisilevsky R. (1990) Apolipoprotein A-I and apo-
lipoprotein SAA half-lives during acute inflammation and
amyloidogenesis. Biochim. Biophys. Acta 1043(3), 295-300.
66. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S,
McHutchison JG. (2007) Albinterferon alpha-2b: a genetic
fusion protein for the treatment of chronic hepatitis C. Nat.
Biotechnol. 25(12), 1411-1419.
Search WWH ::
Custom Search